Infant formula recall comments
This article was originally published in The Tan Sheet
Executive Summary
FDA is soliciting comments on infant formula recall requirements, according to a Feb. 1 Federal Register notice. Current rules require firms to address the hazard to human health, provide a written recall strategy and promptly notify each account. Also, the district office should be notified within 24 hours of the recall; receive written copies of the recall strategy; and receive written reports on the status at least every two weeks until the recall is terminated. Comments are due in 60 days...
You may also be interested in...
Formula recall rules
Infant formula recall requirements have been approved by the Office of Management & Budget, FDA announces in the Aug. 23 Federal Register. The agency requested OMB's approval on several information collection requirements, including reporting health risks to FDA district offices within 24 hours; submitting written reports to the agency; and keeping distribution records for at least one year after the formula's expiration date "to facilitate location of the product being recalled." Based on the past three years, FDA estimates that there will be two recalls per year that would carry a cost of $237,711 to the federal government per recall. The estimated compliance cost for manufacturers is $631,003 per year, according to FDA. The agency solicited comments on the requirements in February, but received none (1"The Tan Sheet" Feb. 7, 2005, In Brief)...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.